Rua Life Sciences PLC
LSE:RUA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (0), the stock would be worth GBX-0.11 (101% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -7.9 | GBX19 |
0%
|
| Industry Average | 0 | GBX-0.11 |
-101%
|
| Country Average | 0 | GBX-0.07 |
-100%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
|
Rua Life Sciences PLC
LSE:RUA
|
11.8m GBP | -7.9 | -54.1 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
62.4B USD | 0 | 0 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.8T JPY | 34.1 | 39.1 | |
| CH |
|
Alcon AG
SIX:ALC
|
30.5B CHF | 29 | 38.9 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
98.2B DKK | 15.4 | 24.5 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
13.9B USD | 20.4 | 34 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.5B GBP | 18.6 | 34.2 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.7B USD | 54.9 | -15.7 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8.3T KRW | -79.5 | -37.5 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
895.2B JPY | 32.6 | 50.6 | |
| US |
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
5.3B USD | 17.7 | 22.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0 |
| Median | 0 |
| 70th Percentile | 0.1 |
| Max | 1 015 |
Other Multiples
Rua Life Sciences PLC
Glance View
RUA Life Sciences Plc is a holding company, which engages in the commercialization of biomedical polymer technology, components, and medical devices. The company is headquartered in Ayrshire, Ayrshire and currently employs 32 full-time employees. The firm is a manufacturer of medical devices and licensor of its IP and know-how together with developing medical devices utilizing its polymer IP. The firm operates through four businesses. Its RUA Medical business provides sub-contract manufacturing, assembly, packing and services to the medical device sector from its Class seven and eight cleanroom suites. Its RUA Biomaterials is the depository of the IP and licensing rights to a range of biostable, implantable polymers, including Elast-EonTM and ECSilTM. Its RUA Vascular business is the legal manufacturer and IP holder of the Company’s cardiovascular and soft tissue patches and bore vascular grafts. Its RUA Structural Heart business holds the intellectual property relating to the Company’s synthetic heart valve technology.
